What Dark Horse Consulting Group does

Dark Horse Consulting Group (DHCG) is a privately held, PE-backed biopharmaceutical consulting firm founded in 2014 by Anthony Davies, Ph.D., and headquartered in Campbell, California. The firm is purpose-built around cell and gene therapy (CGT) and adjacent advanced biotherapeutics, providing expert advisory across CMC, regulatory affairs, nonclinical development, clinical operations, quality and compliance, supply chain, commercial launch, and business analytics. Its client base spans early-stage biotech companies, established biopharmaceutical firms, tools and technology providers, and venture capital and private equity investors that require independent technical and regulatory diligence on CGT platforms.

DHCG delivers its services through a multi-divisional operating model. The flagship Dark Horse Consulting division focuses on CGT; BioTechLogic, acquired in October 2024 with backing from WestView Capital Partners, contributes 20+ years of biopharmaceutical CMC and manufacturing expertise; Converge Consulting provides life sciences strategy and execution; and DHC Regenerative Medicine (the integrated former Bruder Consulting & Venture Group, acquired January 2026) extends the platform into regenerative medicine, tissue repair, and biomaterials. The firm also has international operations in the United Kingdom (DHC Europe) and Asia Pacific (DHC Asia Pacific, established 2023) with a Japan presence added via the April 2026 acquisition of CJ PARTNERS. China capabilities have been expanded through three 2026 MOUs with Porton Advanced, KunTuo (an IQVIA subsidiary), and Altruist Biologics.

Monetization is driven by project-based and retainer consulting engagements priced on a quote-driven basis, with multi-year contracts typical, complemented by a small productized portfolio: the ICMC independent CDMO certification program, CentaurAI for AI-assisted biotherapeutics consulting, PEGASi for quantitative data modeling, and QMS in a Box for quality system acceleration. The firm is sponsored by WestView Capital Partners and earlier by Arcline Investment Management, and revenues are reinvested into acquisitions, geographic expansion, and proprietary tooling that extend DHCG's authority in the CGT consulting category.

Name

Dark Horse Consulting Group

Legal name

Dark Horse Consulting Group

Website

https://darkhorseconsultinggroup.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

51–100 employees

Short description

Dark Horse Consulting Group (DHCG) is a biopharmaceutical consulting firm specializing in cell and gene therapy, providing CMC, regulatory, nonclinical, clinical, quality, supply chain, and commercial advisory to biopharma developers, tools providers, and life sciences investors.

Ownership category

akta.pro rank

Headquarters

HQ city

Campbell

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Others

Revenue model

1. Consulting Services: DHCG generates revenue through project-based and retainer consulting engagements across the biopharma development lifecycle. Services span CMC, regulatory, nonclinical, clinical, quality & compliance, supply chain, commercial launch, and business analytics for cell and gene therapy, biologics, vaccines, and regenerative medicine developers.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Dark Horse Consulting Group (DHCG) is a specialized biopharmaceutical consultancy providing end-to-end consulting services across the cell and gene therapy (CGT) development lifecycle. Its offerings span CMC, regulatory, nonclinical, clinical, quality and compliance, supply chain, commercial launch, and business analytics, augmented by proprietary tools (ICMC certification, CentaurAI, PEGASi, QMS in a Box) and acquired divisions (BioTechLogic, Converge Consulting, DHC Regenerative Medicine, CJ PARTNERS).

Product overview

Dark Horse Consulting Group is a biopharmaceutical consulting organization offering a unified platform of specialized consulting services with multiple integrated brands and tools. The core offering centers on DHC's CGT-focused consulting across CMC, regulatory, nonclinical, clinical, quality & compliance, supply chain, commercial launch, and business analytics. This is augmented by acquired brands BioTechLogic (biopharmaceutical CMC and manufacturing consulting) and Converge Consulting (strategy and execution), plus the DHC Regenerative Medicine division (formerly Bruder Consulting). The portfolio also includes proprietary tools: ICMC (certification program for CDMO capabilities), CentaurAI (AI-powered intelligence), QMS in a Box (quality management system solution), and PEGASi (data-modeling application for capacity and cost analysis).

Differentiator

Problem solved

Functional benefit

Brands

• ICMC (Initiative for Certification of Manufacturing Capabilities): Independent certification program for evaluating CDMO capabilities for advanced therapeutics manufacturing, providing structured assessment of manufacturing site systems including quality, facilities, production, and laboratory controls
• CentaurAI
• QMS in a Box
• PEGASi
• BioTechLogic
• Converge Consulting
• DHC Regenerative Medicine

Products and services

• Dark Horse Consulting (DHC) Primary biopharma consulting brand offering expert consulting across CMC, regulatory, nonclinical, clinical, quality and compliance, supply chain, commercial launch, and business analytics for cell and gene therapy developers.
• BioTechLogic Biopharmaceutical CMC and manufacturing consulting brand with over 20 years of industry experience, offering strategic, practical, and hands-on expertise in technical operations, manufacturing, analytical, and regulatory resources for biologics and vaccines.
• Converge Consulting Life Sciences consulting firm providing strategy, operations, and execution expertise that bridges sound strategy and reliable execution for biopharmaceutical companies.
• DHC Regenerative Medicine Department specializing in regenerative medicine, tissue repair, and biomaterials consulting with expertise in biologics, devices, and combination products for orthopedic, wound care, and plastic surgery markets.
• CJ PARTNERS Consulting and advisory practice specializing in bridging Western and Eastern therapeutic developers, providing market analysis, strategic partnering, regulatory advisory, and clinical operations services across the Asia-Pacific region, particularly Japan.
• ICMC (Initiative for Certification of Manufacturing Capabilities) Independent certification program providing structured and objective assessment of CDMO manufacturing site systems including quality, facilities, production, and laboratory controls for advanced therapeutics.
• CentaurAI AI-powered tool for biotherapeutics consulting, enabling advanced data analysis and intelligence capabilities to support client decision-making.
• QMS in a Box Pre-configured Quality Management System packaged solution providing ready-to-implement frameworks for biopharmaceutical compliance.
• PEGASi Proprietary data-modeling application designed to model uncertainty by applying customized input assumptions to quantitatively describe probable outcomes, used for capacity planning, COGs analysis, build vs. buy analytics, market analysis, and profit margin modeling.

Quantifiable outcome

• 55+ breakthrough therapy products supported across biopharmaceutical development
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core.

• Altruist Biologics (additional announcement in Indonesian language source)coreStrategic or Co-development Partner · 4 June 2026Announcement of the DHCG and Altruist Biologics partnership in Indonesian, reaffirming the strategic collaboration to advance biologics manufacturing and development in China.
• Altruist BiologicscoreStrategic or Co-development Partner · 3 June 2026DHCG and Altruist Biologics signed a Memorandum of Understanding (June 2026) to establish a strategic collaboration accelerating biologics development and global commercialization. The partnership combines DHCG's regulatory, CMC, and consulting expertise with Altruist's cGMP manufacturing infrastructure in China, including facilities in Suzhou and Hangzhou with a total production capacity of 232,000 liters. The collaboration helps sponsor companies navigate NMPA requirements and leverage China's biomanufacturing capabilities to compress timelines and reduce risk.
• Andelyn BiosciencescoreStrategic or Co-development Partner · 13 May 2026Andelyn Biosciences, a cell and gene therapy contract development and manufacturing organization (CDMO), received full certification under DHCG's Initiative for Certification of Manufacturing Capabilities (ICMC) program in May 2026. The certification recognizes Andelyn's capability to support advanced therapies manufacturing with quality and production systems aligned with global regulatory standards. The ICMC program addresses an industry-wide gap in independent evaluation of CDMO capabilities for advanced therapeutics.
• Porton AdvancedcoreStrategic or Co-development Partner · 12 May 2026DHCG and Porton Advanced signed a Memorandum of Understanding (May 2026) to accelerate cell and gene therapy development with emphasis on enabling Investigator-Initiated Trials (IITs) in China. The partnership combines DHCG's regulatory, CMC, and clinical consulting capabilities with Porton Advanced's end-to-end GMP manufacturing infrastructure for ATMPs including viral vectors, cell therapies, and mRNA/LNP products. Porton Advanced has secured 24 IND clearances across NMPA and FDA and supported over 30 IITs.
• KunTuo Medical Research and Development (Beijing) Co., Ltd.coreStrategic or Co-development Partner · 11 May 2026DHCG and KunTuo signed a Memorandum of Understanding (May 2026) to provide biotherapeutics developers with an integrated pathway to conducting clinical trials in China. The partnership combines DHCG's global regulatory, CMC, and consulting expertise with KunTuo's clinical research capabilities across China, including specialized CGT clinical trial experience dating back to 2018. KunTuo is a wholly owned subsidiary of IQVIA established in 2011 and has provided over 1,000 clinical research services.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Charles River Associates (CRA): CRA's Life Sciences practice provides management and economic consulting to biopharma clients on regulatory, commercial, and strategic issues. CRA is the closest large-cap analog to DHCG's specialized advisory model.
• Trinity Life Sciences: Trinity provides strategic and scientific consulting to biopharma, with strong regulatory and commercial launch capabilities. Comparable to DHCG's CMC/regulatory/commercial launch service mix.
• Back Bay Life Science Advisors: Specialized life sciences advisory firm focused on strategy, commercial, and transaction support for biopharma companies and investors. Overlaps with DHCG's PE/VC diligence and strategy services.
• Lumanity: Lumanity (formerly known as Datamonitor Healthcare/DRG) provides evidence-based consulting to biopharma across clinical, regulatory, and commercial domains, with PE-backed growth similar to DHCG.
• Outcome Capital: Specialized life sciences advisory and investment banking firm serving emerging biotech and investors. Comparable to DHCG's PE/VC diligence and strategy services for the biotech buyer side.
• Locust Walk: Locust Walk is a life sciences-focused transaction advisory firm supporting biopharma companies and investors on deals and strategic partnering — directly comparable to DHCG's CGT commercial/strategy services.

Broad incumbents

• Navigant / Guidehouse (Life Sciences): Guidehouse's Life Sciences segment provides broad management and strategic consulting to pharma/biotech including regulatory and commercial advisory. Larger incumbent that competes for similar enterprise mandates.
• McKinsey & Company (Pharma & Medical Products): McKinsey's global Pharma practice advises large biopharma on R&D, regulatory, manufacturing, and commercial strategy. Represents the high-end incumbent competitive threat to DHCG's enterprise clients.
• Boston Consulting Group (Health Care): BCG's Health Care practice covers biopharma strategy, operations, and organization design. Competes with DHCG for top-tier biopharma client relationships, particularly on commercial launch and portfolio strategy.
• Cytiva (Danaher Life Sciences): Cytiva provides tools, technologies, and services for biotherapeutics development and manufacturing, and increasingly offers consulting-adjacent services. Represents an emerging large-incumbent competitor in the CGT value chain.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/dark-horse-consulting-group-inc
• Xx.com/darkhorsecagt

Revenue estimate

Valuation estimate

Number of profiles

Profiles20 records

Subsidiaries4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dark Horse Consulting Group